IRCT20220209053979N6
Completed
未知
Bioequivalence Study of Escitalopram 10 mg of Pars Darou and Cipralex manufactured by Lundbeck in 24 Healthy Volunteers
Pars Darou Company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- A crossover bioequivalence study in 24 healthy volunteers.
- Sponsor
- Pars Darou Company
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Laboratory tests \+/\- 10% of normal interval
- •Without any history of chronic sickness
Exclusion Criteria
- •History of medicine consumption
- •Donation of blood sample more than 300 ml within last 30 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Bioequivalence Study of 10 mg Escitalopram Oxalate Film Coated Tablets in Healthy VolunteersHealthy volunteersTCTR20161025003Medifive Pharma Co., Ltd.24
Not yet recruiting
Not Applicable
Comparative in vivo evaluation of 2 Escitalopram 20 mg F.C. Tablet formulations.IRCT20180620040164N44Karen Pharma and Food Supplement Co.24
Not yet recruiting
Not Applicable
Comparative in vivo evaluation of 2 Escitalopram 20 mg F.C. Tablet formulations.Mood disorder due to known physiological condition with major depressive-like episode.Mood disorder due to known physiological condition with major depressive-like episodeF06.32IRCT20180620040164N39Actover Pharmaceutical Co.24
Completed
Phase 2
Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticismeuroticism or neuroticism.Post-traumatic stress disorder, acuteF43.11IRCT20211208053331N1Ahvaz University of Medical Sciences172
Recruiting
Phase 3
Treatment of depressive symptoms in patients with heart failureDepression.Major depressive disorder, single episode, mildF32.0IRCT20190525043700N5Babol University of Medical Sciences80